{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'CLINICAL TRIAL PROTOCOL', 'TITLE:', 'A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment', 'of Metastatic Renal Cell Carcinoma (ProSun Study)', 'PROTOCOL IDENTIFYING NUMBER:', 'PS-001', 'PROTOCOL VERSION NUMBER:', 'v1.0', 'PROTOCOL DATE:', '10 Sep 2017', 'PROTOCOL AUTHOR:', 'Pawet Chrom', 'DEVELOPMENT PHASE', '2', 'Page 1 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Table of Contents', 'CLINICAL TRIAL PROTOCOL', '1', 'Table of Contents', '2', 'List of Abbreviations', '5', 'Statement of Compliance', '8', 'Study Contact List', '9', 'Clinical Trial Summary', '11', '1. Background', '13', '1.1 Renal Cell Carcinoma', '13', '1.1.1 Epidemiology', '13', '1.1.2 The Role of VHL-HIF Axis in the Pathogenesis of RCC', '13', '1.1.3 The Role of Beta-adrenergic Receptors in Carcinogenesis', '14', '1.1.4 The Place of Sunitinib in Treatment of Metastatic RCC', '15', '1.2 Propranolol', '16', '1.2.1 Pharmacology', '16', '1.2.2 Current Indications and Dosing', '17', '1.2.3 Antineoplastic Potential', '17', '1.2.4 Safety Results', '19', '1.3 Study Rationale', '20', '2. Study Objectives', '23', '2.1 Primary Objective', '23', '2.2 Secondary Objectives', '23', '3. Study Design', '23', '3.1 Summary of Study Design', '23', '3.2 Length of the Study', '24', '3.3 Study Extension', '24', '4. Study Population', '24', '4.1 Number of Patients Planned', '24', '4.2 Recruitment of Patients', '24', '4.3 Inclusion Criteria', '24', '4.4 Exclusion Criteria', '25', '4.5 Discontinuations', '27', '4.5.1 Discontinuation of Patients', '27', '4.5.2 Replacement of Patients', '27', '4.5.3 Discontinuation of the Study', '27', '5. Study Interventions', '27', '5.1 Investigational Products', '27', '5.1.1 Sunitinib (SUTENTR by Pfizer Inc.)', '27', '5.1.2 Propranolol (Propranolol Accord\u00ae by Accord Healthcare Ltd.)', '28', '5.2 Concomitant Treatment', '29', '5.2.1 Prohibited Concomitant Treatment', '29', '5.2.2 Permitted Concomitant Treatment', '30', '5.3 Storage, Accountability and Compliance', '30', 'Page 2 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '6. Study Measures', '30', '6.1 Definitions of Efficacy Measures', '30', '6.1.1 Objective Response Rate', '30', '6.1.2 Progression-free Survival', '30', '6.1.3 Overall Survival', '30', '6.1.4 Disease Control Rate', '30', '6.2 Safety Measures', '30', '6.3 Health-related Quality of Life Measures', '31', '6.4 Disease-related Stress Measures', '31', '6.5 Tumour Tissue and Serum Biomarkers Assessments', '31', '6.6 Timing and Methods of Measurements', '31', '6.6.1 Pre-treatment Period', '31', '6.6.2 Treatment Period', '32', '6.6.3 Postdiscontinuation Period', '33', '6.6.4 Unscheduled Visits or Assessments', '34', '7. Adverse Events', '34', '7.1 Adverse Events Definitions', '34', '7.2 Expected Adverse Events', '34', '7.2.1 Expected Adverse Events for Sunitinib', '34', '7.2.2 Expected Adverse Events for Propranolol', '36', '7.3 Adverse Events Management', '38', '7.4 Adverse Events Monitoring and Reporting', '38', '8. Statistical Considerations', '38', '8.1 Study Hypotheses', '38', '8.2 Sample Size Calculation', '39', '8.3 General Considerations', '39', '8.4 Primary and Secondary Enppoints Analyses', '39', '8.4.1 ORR and DCR Analysis', '39', '8.4.2 PFS and os Analysis', '40', '8.4.3 Safety Analysis', '40', '8.4.4 Health-related Quality of Life Analysis', '40', '8.4.5 Disease-related Stress Analysis', '40', '8.4.6 Biomarker Analyses', '41', '8.5 Interim Analysis', '41', '8.6 Statistical Software', '41', '9. Ethical and Regulatory Standards', '41', '9.1 Ethics Review', '41', '9.2 Ethical Conduct of the Study', '41', '9.3 Subject Information and Consent', '41', '9.4 Laws and Regulations', '41', '9.5 Conditions for Modifying the Protocol', '42', '9.6 Insurance', '42', '10. Bibliographic References', '42', 'Appendix A: Schedule of Assessments', '48', 'Page 3 of 60']\n\n###\n\n", "completion": "END"}